The Impact of SARS-CoV-2 on Immune and Kidney Health

Immune Response to SARS-CoV-2 Infection

The immune response to SARS-CoV-2 is characterized by a complex interplay between innate and adaptive immunity. Upon infection, the virus enters respiratory epithelial cells, triggering a rapid immune response. This initial response is mediated by pattern recognition receptors (PRRs) that detect viral components, leading to the activation of signaling pathways such as NF-κB and IRF3. These pathways result in the production of type I interferons (IFNs), particularly IFN-α and IFN-β, which play a pivotal role in establishing an antiviral state in neighboring cells (Naiditch et al., 2024).

A robust adaptive immune response follows the innate response, involving the activation of CD4+ T helper cells and CD8+ cytotoxic T lymphocytes. These activated T cells are crucial for the clearance of infected cells and the generation of memory responses. However, studies have shown that SARS-CoV-2 can induce lymphopenia, particularly affecting CD8+ T cells and natural killer (NK) cells, which is associated with severe disease outcomes (Naiditch et al., 2024).

Inflammatory Mechanisms in COVID-19 Severity

The severity of COVID-19 is heavily influenced by the inflammatory response triggered by SARS-CoV-2. In patients with severe illness, a hyperinflammatory state, often referred to as a “cytokine storm,” occurs. This is characterized by elevated levels of pro-inflammatory cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) (Naiditch et al., 2024). These cytokines are primarily produced by immune cells such as macrophages and T cells, leading to systemic inflammation and potential tissue damage.

The exaggerated immune response can result in acute respiratory distress syndrome (ARDS), multi-organ failure, and acute kidney injury (AKI). The kidneys are particularly vulnerable due to their high expression of the angiotensin-converting enzyme 2 (ACE2) receptor, which facilitates viral entry. The interplay between inflammation and kidney health is critical, as inflammatory cytokines can lead to tubular injury and worsen kidney function in patients with COVID-19 (Naiditch et al., 2024).

Table 1: Key Cytokines and Their Roles in COVID-19 Severity

Role of Cytokines and Endothelial Cells in COVID-19

Cytokines produced during SARS-CoV-2 infection play a dual role in host defense and pathogenesis. While they are essential for controlling viral replication and initiating repair processes, their overproduction can lead to vascular dysfunction and contribute to systemic complications. Endothelial cells, which line blood vessels, express ACE2 and can be directly infected by the virus. This infection leads to endothelial dysfunction, characterized by increased permeability, inflammation, and thrombosis, further exacerbating the severity of COVID-19 (Naiditch et al., 2024).

The interaction between cytokines and endothelial cells is critical in the pathophysiology of COVID-19. Elevated cytokine levels can lead to endothelial activation and dysfunction, resulting in the formation of neutrophil extracellular traps (NETs) and microthrombi, which can compromise organ perfusion, including that of the kidneys (Naiditch et al., 2024).

Kidney Damage and Acute Tubular Injury from SARS-CoV-2

Acute kidney injury (AKI) has emerged as a frequent complication of COVID-19, affecting approximately 20-30% of hospitalized patients. The mechanisms underlying SARS-CoV-2-induced kidney damage are multifactorial, including direct viral infection of renal cells, systemic inflammation, and hypoxia due to ARDS (Naiditch et al., 2024). Direct infection of renal tubular epithelial cells via ACE2 facilitates viral replication, leading to cellular injury and apoptosis.

Histopathological examinations of kidney biopsies from COVID-19 patients have revealed acute tubular injury, characterized by tubular dilatation, epithelial cell detachment, and inflammatory infiltrates. These findings highlight the role of the virus in promoting kidney damage, which can lead to persistent renal impairment even after recovery from acute illness (Naiditch et al., 2024).

Table 2: Mechanisms of Kidney Injury in COVID-19

Strategies for Mitigating COVID-19 Related Kidney Issues

Addressing COVID-19-related kidney complications requires a multifaceted approach. Early recognition and management of AKI are crucial. Supportive care, including fluid management and monitoring of renal function, can help mitigate the effects of kidney injury. Additionally, the use of anti-inflammatory therapies, such as corticosteroids, has been shown to improve outcomes in severe COVID-19 cases by dampening the hyperinflammatory response (Naiditch et al., 2024).

Preventive strategies, including vaccination against SARS-CoV-2, are critical to reducing the incidence of severe disease and its associated complications. Vaccines enhance the adaptive immune response and can reduce the risk of severe cytokine storms, thereby protecting renal health (Naiditch et al., 2024). Furthermore, ongoing research into the long-term effects of COVID-19 on kidney health and the development of targeted therapies is essential.

FAQ Section

How does SARS-CoV-2 affect the immune system? SARS-CoV-2 triggers an immune response involving both innate and adaptive mechanisms, leading to the production of cytokines and activation of T cells. However, an exaggerated response can result in a cytokine storm, contributing to severe disease.

What is the connection between COVID-19 and kidney damage? COVID-19 can lead to acute kidney injury through direct viral infection of renal cells, inflammation, and endothelial dysfunction, which can compromise renal blood flow and function.

How can kidney injuries from COVID-19 be mitigated? Early detection and supportive care, including managing fluid balance and monitoring renal function, are vital. Anti-inflammatory therapies and vaccination can also help reduce complications.

Are there long-term effects of COVID-19 on kidney health? Yes, some patients experience persistent renal impairment after recovering from COVID-19, highlighting the need for ongoing monitoring and research into long-term kidney health.

References

1. Naiditch, H., Betts, M. R., Larman, H. B., Levi, M., & Rosenberg, A. Z. (2024). Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease. Frontiers in Immunology, 16, 1376654. https://doi.org/10.3389/fimmu.2024.1376654
2. Lembas, A., Załęski, A., Mikuła, T., Kozłowska, J., & Wiercińska-Drapało, A. (2025). Proinflammatory Biomarkers and Clinical Factors Associated with Long-Term Mortality in People with HIV. Viruses, 17(2), 243. https://doi.org/10.3390/v17020243
3. Han, J., Zhang, Z., Liu, X., Yang, H., & Liu, L. (2025). Prediction of Pharmacokinetics for CYP3A4-Metabolized Drugs in Pediatrics and Geriatrics Using Dynamic Age-Dependent Physiologically Based Pharmacokinetic Models. Pharmaceutics, 17(2), 214. https://doi.org/10.3390/pharmaceutics17020214
4. Peng, L., Martinez, L., Xue, H., Liu, Q., Ding, X., Pan, J., Ding, H., & Wang, J. (2025). Comparative evaluation of QuantiFERON-TB gold in-tube plus for Mycobacterium tuberculosis infection among adolescents in China. BMC Public Health, 25(1), 21954. https://doi.org/10.1186/s12889-025-21954-7
5. Goh, E., Chavatte, J.-M., Lin, R. T. P., Ng, L. F. P., & Oon, H. H. (2025). Vaccines in Dermatology—Present and Future: A Review. Vaccines, 13(2), 125. https://doi.org/10.3390/vaccines13020125